69 related articles for article (PubMed ID: 34909679)
1. Methods in marine natural product drug discovery: what's new?
Almaliti J; Gerwick WH
Expert Opin Drug Discov; 2023 Jul; 18(7):687-691. PubMed ID: 37194298
[No Abstract] [Full Text] [Related]
2. Sec61 Inhibitor Apratoxin S4 Potently Inhibits SARS-CoV-2 and Exhibits Broad-Spectrum Antiviral Activity.
Pohl MO; Martin-Sancho L; Ratnayake R; White KM; Riva L; Chen QY; Lieber G; Busnadiego I; Yin X; Lin S; Pu Y; Pache L; Rosales R; Déjosez M; Qin Y; De Jesus PD; Beall A; Yoh S; Hale BG; Zwaka TP; Matsunaga N; García-Sastre A; Stertz S; Chanda SK; Luesch H
ACS Infect Dis; 2022 Jul; 8(7):1265-1279. PubMed ID: 35766385
[TBL] [Abstract][Full Text] [Related]
3. Canine osteosarcoma cells exhibit basal accumulation of multiple chaperone proteins and are sensitive to small molecule inhibitors of GRP78 and heat shock protein function.
Mattos DR; Weinman MA; Wan X; Goodall CP; Serrill JD; McPhail KL; Milovancev M; Bracha S; Ishmael JE
Cell Stress Chaperones; 2022 May; 27(3):223-239. PubMed ID: 35244890
[TBL] [Abstract][Full Text] [Related]
4. Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer.
Miller MA; Sullivan RJ; Lauffenburger DA
Clin Cancer Res; 2017 Feb; 23(3):623-629. PubMed ID: 27895032
[TBL] [Abstract][Full Text] [Related]
5. Nuclear receptor tyrosine kinase transport and functions in cancer.
Chen MK; Hsu JL; Hung MC
Adv Cancer Res; 2020; 147():59-107. PubMed ID: 32593407
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cotranslational translocation by apratoxin S4: Effects on oncogenic receptor tyrosine kinases and the fate of transmembrane proteins produced in the cytoplasm.
Cai W; Ratnayake R; Wang M; Chen QY; Raisch KP; Dang LH; Law BK; Luesch H
Curr Res Pharmacol Drug Discov; 2021; 2():100053. PubMed ID: 34909679
[TBL] [Abstract][Full Text] [Related]
7. Apratoxin S10, a Dual Inhibitor of Angiogenesis and Cancer Cell Growth To Treat Highly Vascularized Tumors.
Cai W; Chen QY; Dang LH; Luesch H
ACS Med Chem Lett; 2017 Oct; 8(10):1007-1012. PubMed ID: 29057042
[TBL] [Abstract][Full Text] [Related]
8. Apratoxin a reversibly inhibits the secretory pathway by preventing cotranslational translocation.
Liu Y; Law BK; Luesch H
Mol Pharmacol; 2009 Jul; 76(1):91-104. PubMed ID: 19403701
[TBL] [Abstract][Full Text] [Related]
9. Systematic Chemical Mutagenesis Identifies a Potent Novel Apratoxin A/E Hybrid with Improved in Vivo Antitumor Activity.
Chen QY; Liu Y; Luesch H
ACS Med Chem Lett; 2011 Nov; 2(11):861-865. PubMed ID: 22081789
[TBL] [Abstract][Full Text] [Related]
10. Apratoxin S4 Inspired by a Marine Natural Product, a New Treatment Option for Ocular Angiogenic Diseases.
Qiu B; Tan A; Veluchamy AB; Li Y; Murray H; Cheng W; Liu C; Busoy JM; Chen QY; Sistla S; Hunziker W; Cheung CMG; Wong TY; Hong W; Luesch H; Wang X
Invest Ophthalmol Vis Sci; 2019 Jul; 60(8):3254-3263. PubMed ID: 31361305
[TBL] [Abstract][Full Text] [Related]
11. Exploring the "Other" subfamily of HECT E3-ligases for therapeutic intervention.
Singh S; Ng J; Sivaraman J
Pharmacol Ther; 2021 Aug; 224():107809. PubMed ID: 33607149
[TBL] [Abstract][Full Text] [Related]
12. The CDCP1 Signaling Hub: A Target for Cancer Detection and Therapeutic Intervention.
Khan T; Kryza T; Lyons NJ; He Y; Hooper JD
Cancer Res; 2021 May; 81(9):2259-2269. PubMed ID: 33509939
[TBL] [Abstract][Full Text] [Related]
13. Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin A.
Kazemi S; Kawaguchi S; Badr CE; Mattos DR; Ruiz-Saenz A; Serrill JD; Moasser MM; Dolan BP; Paavilainen VO; Oishi S; McPhail KL; Ishmael JE
Biochem Pharmacol; 2021 Jan; 183():114317. PubMed ID: 33152346
[TBL] [Abstract][Full Text] [Related]
14. Targeting of the E3 ubiquitin-protein ligase HUWE1 impairs DNA repair capacity and tumor growth in preclinical multiple myeloma models.
Kunz V; Bommert KS; Kruk J; Schwinning D; Chatterjee M; Stühmer T; Bargou R; Bommert K
Sci Rep; 2020 Oct; 10(1):18419. PubMed ID: 33116152
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
